Friday, Apr 26 2024 | Time 22:42 Hrs(IST)
image
Business EconomyPosted at: Jul 29 2021 5:30PM


Windlas Biotech Limited Initial Public Offer to open on Aug 04

Kolkata, Jul 29 (UNI) Windlas Biotech Limited, a manufacturer of pharmaceutical formulations and
ranks amongst the top five companies in the domestic pharmaceutical formulations Contract Development and Manufacturing Organizations (“CDMO”) industry in India in terms of revenue, proposes to open its Initial Public Offering on August 04.
The Price Band of the Offer has been fixed at Rs 448 to Rs 460 per Equity Share. Bids can be
made for a minimum of 30 Equity Shares and in multiples of 30 Equity Shares thereafter, a
company official here on Thursday said.
The Initial Public Offer consists of Equity Shares of face value of Rs5 each (“Equity Shares”) of Windlas Biotech Limited comprising a fresh issue aggregating up to Rs1,650 million (the “Fresh Issue”) and an offer for sale of up to 5,142,067 Equity Shares (“Offer for Sale” and together with Fresh Issue, the “Offer”).
The Offer for Sale comprises of up to 1,136,000 Equity Shares by Vimla Windlass (the “Individual Selling Shareholder”) and up to 4,006,067 Equity Shares by Tano India Private Equity Fund II (the “Investor Selling Shareholder” and collectively with Individual Selling Shareholder, the “Selling Shareholders”).
The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (the “SEBI ICDR Regulations”) and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”) provided that the Company and the Selling Shareholders, in consultation with the BRLMs, may allocate up to 60% of
the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual
Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with SEBI ICDR Regulations.
In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance
Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net
QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the
remaining QIB Portion for proportionate allocation to QIBs.
Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders (“RIBs”) in accordance with the SEBI ICDR Regulations, subject to valid Bids
being received from them at or above the Offer Price.
All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank accounts and UPI ID (in case of RIBs using UPI Mechanism), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or the Sponsor Bank, as applicable.
Anchor Investors are not permitted to participate in the Offer through the ASBA process.
SBI Capital Markets Limited, DAM Capital Advisors Limited (Formerly IDFC Securities Limited)
and IIFL Securities Limited are the BRLMs to the Offer.
The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on BSE
and NSE.
UNI BM
Please log in to get detailed story.
Tags: #Windlas Biotech Limited Initial Public Offer to open on Aug 04
More News
Sensex nosedives 609 28 pts

Sensex nosedives 609 28 pts

26 Apr 2024 | 5:26 PM

Mumbai, April 26 (UNI) Snapping a winning streak of last five sessions, the BSE Sensex on Friday, the last session of the week, tanked 609.28 pts to settle at 73730.16 amid mixed global cues.

see more..
Maruti Suzuki net profit surges 48 pc to Rs 3,878 crore in Q4

Maruti Suzuki net profit surges 48 pc to Rs 3,878 crore in Q4

26 Apr 2024 | 5:00 PM

New Delhi, April 26 (UNI) On the back of solid volume growth, the country's largest carmaker Maruti Suzuki on Friday reported 47.80% jump in standalone net profit at Rs 3,877.8 crore for January-March period (Q4) of financial year 2023-24.

see more..

Shriram Finance net jumps 57 pc to Rs 2,021 cr in Q4

26 Apr 2024 | 3:52 PM

New Delhi, April 26 (UNI) Shriram Finance on Friday reported 56.91% year-on-year jump in consolidated net profit at Rs 2,021.28 crore for the January-March period (Q4) of financial year 2023-24.

see more..
Maruti Suzuki gets show-cause notice from Legal Metrology dept

Maruti Suzuki gets show-cause notice from Legal Metrology dept

26 Apr 2024 | 2:39 PM

New Delhi, April 26 (UNI) The country's leading carmaker Maruti Suzuki India on Friday said that it has received a show-cause notice from the Legal Metrology office in Rishikesh, Uttarakhand.

see more..

Onkar Kanwar gets Lifetime Achievement Award

26 Apr 2024 | 2:08 PM

Kochi, April 26 (UNI) Chairman of Apollo Tyres Ltd, Onkar Kanwar, has been conferred with the Lifetime Achievement Award at the All India Management Association (AIMA)’s Managing India Awards ceremony.

see more..
image